A prominent neuroscientist has developed the Quick Dementia Rating System to reliably, and quickly, identify patients suffering from dementia.
Developed by James E. Galvin, MD, MPH, the Quick Dementia Rating System (QDRS) uses an evidence-based method to accurately identify and stage patients with dementia. QDRS has applications for use in clinical practice, to prequalify patients in clinical trials, prevention studies, community surveys and biomarker research.
The existing process to evaluate individuals is long and laborious, while QDRS has the advantage of being conducted in a few minutes. "After extensive testing and evaluation of the Quick Dementia Rating System, we have found it to be as effective as the gold standard used today to screen for the five stages of dementia," said Dr Galvin. "This new tool gives you a lot of power to see the same results as a full screening in a fraction of the time it takes for a complete screening." The findings with QDRS have been published in the journal Alzheimer's and Dementia.
The evaluation includes a 10-item questionnaire that can be completed by a caregiver, friend, or family member, and is short enough to be viewed as a single screenshot, maximizing its clinical utility. Scores range from 0 to 30 with higher scores representing greater cognitive impairment. The questionnaire covers: 1) memory and recall; 2) orientation; 3) decision-making and problem-solving abilities; 4) activities outside the home; 5) function at home and hobbies; 6) toileting and personal hygiene; 7) behavior and personality changes; 8) language and communication abilities; 9) mood; and 10) attention and concentration.
Read more at EurekAlert!: http://bit.ly/1ErZzAH
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More
Real-World Evidence Confirms the Benefits of JAK Inhibitors in Patients With Rheumatoid Arthritis
January 16th 2025This systematic review of real-world observational studies demonstrated the effectiveness of Janus kinase (JAK) inhibitors in improving treatment adherence, persistence, clinical outcomes, and patient-reported outcomes among US patients with rheumatoid arthritis.
Read More